Pharmacology News and Research

Latest Pharmacology News and Research

Nitrous oxide anesthesia may lead to increased risk of myocardial infarction: Study

Patients receiving nitrous oxide as part of general anesthesia for surgery may be at increased long-term risk of myocardial infarction (heart attack), reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Jan 2011

Cetero Research completes 20,000th early-phase clinical study

Cetero Research, the leading early-stage contract research organization, today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study.

28 Jan 2011

Arena reduces workforce by 25% and provides update on lorcaserin

Arena Pharmaceuticals, Inc. announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of 2011, of approximately $3.8 million in connection with one-time employee termination costs.

28 Jan 2011

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

28 Jan 2011

Gene signature can accurately predict breast cancer outcomes

Researchers from McGill University's Rosalind and Morris Goodman Cancer Research Centre, the Research Institute of the McGill University Health Centre, the Dana-Farber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not from the burdens associated with unnecessary treatment.

28 Jan 2011

Scientists discover new mechanism neurons use to fine-tune electrical output

Scientists in the Hotchkiss Brain Institute at the Faculty of Medicine, University of Calgary, have discovered a new mechanism that nerve cells (neurons) use to fine-tune their electrical output. The exciting discovery, published this week in the prestigious journal Nature Neuroscience, provides new insights about how the activity of the nervous system is regulated at the cellular level.

27 Jan 2011

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

For 60 years, scientists have puzzled over the possibility of a hepatic osmoreceptor that influences blood pressure regulation. Now, researchers of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, the Experimental and Clinical Research Center of the MDC and Charit- and the Hannover Medical School appear to have made a breakthrough discovery.

27 Jan 2011

Potential therapy to enhance memory and prevent loss of long-term memory

Researchers from Mount Sinai School of Medicine have identified a therapy that may enhance memory and prevent the loss of long-term memory. The research is published in the January 27th issue of Nature.

27 Jan 2011

Anapharm Europe, PharmaNet officially terminate joint venture

PharmaNet Development Group, and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

27 Jan 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

Furiex Pharmaceuticals, Inc. today announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

24 Jan 2011

Mystery of 'inactive' defensin solved

Under standard laboratory conditions, the human beta-defensin 1 (hBD-1), a human antibiotic naturally produced in the body, had always shown only little activity against microbes. Nevertheless the human body produces it in remarkable quantities.

24 Jan 2011

Research findings reveal HIV's hiding spot, new way to stop the virus

HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains such a formidable foe after three decades of research - more than 30 million people worldwide are infected with HIV - it also offers scientists a new, unexpected way to try to stop the virus.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Researchers discover how Ras oncogene chooses a signaling pathway

The National Cancer Institute estimates that more than 43,000 Americans were diagnosed with pancreatic cancer last year and more than 36,000 died from the disease. Despite advances in genetic science showing that the Ras oncogene is mutated in virtually all pancreatic cancers, scientists have been frustrated by the complexity of the signaling pathways in humans, which make it difficult to pinpoint potential therapeutic targets.

20 Jan 2011

Pharmacology News and Research

Latest Pharmacology News and Research

Nitrous oxide anesthesia may lead to increased risk of myocardial infarction: Study

Cetero Research completes 20,000th early-phase clinical study

Arena reduces workforce by 25% and provides update on lorcaserin

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

Gene signature can accurately predict breast cancer outcomes

Scientists discover new mechanism neurons use to fine-tune electrical output

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

Potential therapy to enhance memory and prevent loss of long-term memory

Anapharm Europe, PharmaNet officially terminate joint venture

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation

Mystery of 'inactive' defensin solved

Research findings reveal HIV's hiding spot, new way to stop the virus

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Researchers discover how Ras oncogene chooses a signaling pathway

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Positive preliminary results from Soligenix's SGX202 in GARS model

Women's Health Congress to explore mammography controversy

Pittcon Highlights: Pharmaceutical & Biologic eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Pharmacology News and Research

Latest Pharmacology News and Research

Pittcon Highlights: Pharmaceutical & Biologic eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in